Understanding MPVX Viral Clearance and Evaluating Transmission Dynamics of MPVX and Mpox Vaccine Effectiveness in Sierra Leone (MOVIE-TRACE SALONE).
- Funded by UK Research and Innovation (UKRI)
- Total publications:0 publications
Grant number: UKRI2532
Grant search
Key facts
Disease
mpoxStart & end year
20252027Known Financial Commitments (USD)
$2,692,235.01Funder
UK Research and Innovation (UKRI)Principal Investigator
Edward; Deborah; Gibrilla; Michael Choi; Watson-Jones; Deen; MarksResearch Location
United KingdomLead Research Institution
London School of Hygiene and Tropical MedicineResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Pathogen morphology, shedding & natural history
Special Interest Tags
N/A
Study Type
Unspecified
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Mpox Research Priorities
N/A
Mpox Research Sub Priorities
N/A
Abstract
This proposal links two epidemiological studies and one vaccine effectiveness study aimed at addressing the public health challenge of Mpox in Sierra Leone. The outbreak is ongoing and there is an urgent need to collect these data as soon as possible. The MOVIE-SALONE study focuses on understanding the kinetics of viral elimination, shedding light on how MPXV interacts with host tissues and immune defences, and informing endpoint selection in therapeutic trials. The TRACE-SALONE study aims to determine the Secondary Attack Rate (SAR) in MPXV outbreak settings, assessing host susceptibility within specific populations, offering vital data to target interventions towards vulnerable groups and informing vaccine efforts by contributing to the assessment of vaccine effectiveness endpoints. The third study, VE-SALONE, examines vaccine effectiveness for a single dose of the MVA-BN (JynneosTM) vaccine against MPXV infection and Mpox disease.